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Abstract
Purpose: Permanent interstitial brachytherapy is an appealing treatment modality for patients with locoregional 
recurrent, resectable head and neck carcinoma (HNC), having previously received radiation. Cesium-131 (131Cs) is 
a permanent implant brachytherapy isotope, with a low average photon energy of 30 keV and a short half-life of 
9.7 days. Exposure to medical staff and family members is low; patient isolation and patient room shielding are not 
required. This work presents a single institution’s implementation process of utilizing an intraoperative, permanent 
131Cs implant for patients with completely resected recurrent HNC.
Material and methods: Fifteen patients receiving 131Cs permanent seed brachytherapy were included in this anal-
ysis. The process of pre-planning, selecting the dose prescription, seed ordering, intraoperative procedures, post-im-
plant planning, and radiation safety protocols are described.
Results: Tumor volumes were contoured on the available preoperative PET/CT scans and a pre-implant treatment 
plan was created using uniform source strength and uniform 1 cm seed spacing. Implants were performed intraoper-
atively, following tumor resection. In five of the fifteen cases, intraoperative findings necessitated a change from the 
planned number of seeds and recalculation of the pre-implant plan. The average prescription dose was 56.1 ±6.6 Gy 
(range, 40-60 Gy). The average seed strength used was 2.2 ±0.2 U (3.5 ±0.3 mCi). Patients returned to a recovery room 
on a standard surgical floor and remained inpatients, without radiation safety restrictions, based on standard surgical 
recovery protocols. A post-implant treatment plan was generated based on immediate post-operative CT imaging to 
verify the seed distribution and confirm delivery of the prescription dose. Patients were provided educational infor-
mation regarding radiation safety recommendations.
Conclusions: Cesium-131 interstitial brachytherapy is feasible and does not pose major radiation safety concerns; it 
should be considered as a treatment option for previously irradiated patients with recurrent, resectable HNC. 
J Contemp Brachytherapy 2019; 11, 3: 227–234 
DOI: https://doi.org/10.5114/jcb.2019.85778
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Purpose
Head and neck cancer is the sixth most common can-
cer worldwide [1,2]. Over 800,000 new head and neck 
cancer cases are diagnosed and nearly 450,000 head and 
neck cancer-related deaths occur annually worldwide, 
as of 2018 [1,2]. About two thirds of patients with head 
and neck carcinoma (HNC) are diagnosed at an advanced 
stage of the disease [3]. Surgical resection followed by ra-
diotherapy or post-operative chemoradiation/definitive 
chemoradiation are employed as treatment modalities, 
with curative intent for patients with locally advanced 
disease. Unfortunately, the likelihood of treatment fail-
ure for patients with locally advanced HNC remains 
high, reaching 50%, with locoregional failure and distant 
metastases occurring in 20-30% of patients [3,4,5,6,7,8]. 
Locoregional failure has remained the predominant pat-
tern of failure and it is the most common cause of death 
in HNC patients [9,10]. Patients with recurrent or met-
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astatic HNC have a poor prognosis, with median over-
all survival of less than one year [8,11,12], necessitating 
a pressing need to improve therapy for patients with re-
current HNC. 
Prognosis is particularly poor when the recurrence 
develops in an area previously treated with radiation 
[11,12]. Salvage surgery in previously irradiated cases 
can provide durable disease control in 15% of patients 
with locoregional recurrence in the absence of disease at 
distant sites [3]. Nevertheless, the pathological findings 
following salvage surgery frequently indicate that the pa-
tient requires a second course of post-operative radiation 
due to the unclear or positive surgical margins or other 
adverse pathologic features [3,13]. 
Due to technological advances in radiation oncology 
in the recent years, re-irradiation using external beam 
radiation therapy (EBRT) has become an option. Unfor-
tunately, most studies involving EBRT for re-irradiation 
are retrospective and report on a small patient cohort and 
a single institution experience; the treatment regimens 
and patient characteristics vary considerably between 
studies. Moreover, the treatment-related toxicity may be 
very significant and may include surgical wound healing 
complications, fistula formation, osteoradionecrosis, vas-
cular events, transverse myelitis, brainstem and cranial 
nerve injury, etc. [3,12,14]. 
Brachytherapy has significant advantages over exter-
nal beam radiation therapy, thus should be considered 
when a second course of radiation is indicated [15]. Com-
pared to EBRT, brachytherapy facilitates the delivery of 
a high and localized radiation dose to the target volume. 
The dose to the surroundings tissues is significantly re-
duced due to the characteristic rapid dose falloff [13]. The 
reduced radiation delivery time of brachytherapy relative 
to conventionally fractionated EBRT may increase the ef-
fectiveness of radiotherapy; in particular head and neck 
cancer is known to have relatively short radiobiologically 
estimated repair half-life. Furthermore, given that the hy-
poxic mass of the tumor is removed during salvage sur-
gical resection, hypothetically, only well-oxygenated mi-
croscopic disease remains around the surgical margins. 
Therefore, a lower radiation dose could be sufficient with 
the use of brachytherapy [16]. 
The majority of the published brachytherapy results 
were obtained with low-dose-rate, high-dose-rate, or 
pulsed-dose-rate techniques and manual afterloading 
[17,18,19,20,21,22]. Compared to other isotopes, Cesi-
um-131 (131Cs) is a relatively new permanent seed implant 
brachytherapy isotope, with an average photon energy of 
30 keV and short half-life of 9.7 days [23]. Compared to 
external beam radiation or high-dose-rate brachytherapy 
using Iridium-192, the lower energy photons from 131Cs 
decay allow for more localized deposition of dose, de-
creasing the dose delivered to nearby tissues, and poten-
tially reducing treatment complications. The feasibility of 
131Cs implants for recurrent HNC has been demonstrated 
with acceptably low levels of exposure to staff during the 
procedure [24]. In a small series, re-irradiation using per-
manent 131Cs has been shown to provide similar rates of 
survival with decreased toxicity, compared to prior liter-
ature [25]. 
The purpose of this report is to describe a single in-
stitution’s implementation process of utilizing intra-
operative, permanent 131Cs seed implants for patients 
with completely resected recurrent HNC. The process of 
pre-planning, pre-implant seed ordering, intraoperative 
procedures, post-implant planning, and radiation safety 
protocol are described. 
Material and methods 
Patients were treated per an institutional protocol 
for recurrent resectable HNC. Fifteen patients receiving 
131Cs permanent seed brachytherapy were included in 
this analysis. 
Description of the experimental product 
IsoRay™ (Richland, WA) provides the sterilized 
Proxcelan™ 131Cs [23] seeds used in all implants in either 
strands or a mesh. Seeds contain an inorganic substrate 
adsorbed with the radioactive 131Cs isotope and a 4 mm 
radio-opaque gold marker encased in a 0.05 mm titani-
um capsule, as seen in Figure 1. The outer diameter and 
length of the capsule are 0.82 mm and 4.5 mm, respective-
ly. The vendor manufactures the seeds and places them 
into 3-0 vicryl strands at 1 cm intervals or in a mesh with 
user-defined spacing and positioning. The strands or 
mesh can then be sutured directly into the resection bed. 
Implant pre-planning and dose prescription
Tumor volumes were identified on a preoperative 
positron emission tomography/computed tomography 
(PET/CT) scan. The estimated size and location of the 
resection cavity were estimated by the radiation oncol-
ogist and otorhinolaryngology surgeon, and the optimal 
plane to suture stranded seeds or a mesh was identified. 
A surgical mesh is available for purchase with custom-
izable seed and strand spacing. The constructed mesh is 
then provided to the institution sterilized. The decision 
to utilize stranded seeds or a predesigned mesh depends 
on surgeon preference as well as implant location. An im-
plant that spans across the carotid artery is an example 
of one location that may benefit from strands of seeds in-
Fig. 1. Proxcelan™ 131Cs source diagram, courtesy of 
IsoRay™
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stead of a mesh, allowing for strands to be individually 
sutured on either side of the critical structure with ade-
quate spacing. 
Using MIM Symphony LDR™ treatment planning 
software, version 6.5 (Cleveland, OH, USA) [26,27], the 
seeds were placed in a single, optimal plane with 1 cm 
seed-to-seed spacing to cover the estimated resection cav-
ity. The seed air kerma strength was iteratively adjusted 
in the planning software, such that a dose of 60 Gy was 
delivered to a prescription located 5 mm perpendicular 
to the center of the implant plane. Planning details have 
previously been reported [28]. The treatment plan was 
reviewed by the medical physicist, radiation oncologist, 
and otorhinolaryngology surgeon. The prescription dose 
was decreased in cases where there was a concern for 
normal tissue toxicity by the radiation oncologist. In most 
cases, especially those with larger uncertainty in the size 
or geometry of the estimated resection cavity, an extra 
strand of seeds was ordered. 
Seed ordering and receipt 
Sources were ordered five to seven business days 
prior to implant date from IsoRay™ for each patient. 
Radioactive materials were delivered to the radiation 
safety office per institutional protocols, including wipe 
tests and source inventory recording. Sources were then 
transferred to the department of radiation oncology, ac-
cepted by a medical physicist, logged in the source in-
ventory, and stored in a secure location designated for 
radioactive material. Non-sterile, loose seeds from the 
same lot as the implant seeds were ordered and assayed 
for verification of vendor-stated activity. The number of 
assayed seeds was either 10% of the number of seeds in 
the implant or five seeds, whichever was larger [29]. As-
says were performed using an accredited dosimetry cal-
ibration laboratory-calibrated HDR 1000 Plus well-type 
ionization chamber and Max-4000 electrometer for each 
patient seed order prior to implant, with an average dif-
ference of 1.2 ±1.1% from vendor-specified activity. This 
was documented by a medical physicist and included in 
the patient’s chart. The un-assayed sources for implant 
remained in the sterile packaging from the vendor and 
were transported to the operating room under the super-
vision of a medical physicist after the completion of the 
surgical resection. Cesium-131 storage is restricted and 
based only upon institutional policies and governmental 
regulations for storing radioactive material; there are no 
limitations on environmental conditions such as light or 
temperature. 
Intraoperative procedures 
Implants were performed intraoperatively, imme-
diately following tumor resection. Patients underwent 
maximally safe resection of the tumor as determined by 
the otorhinolaryngology surgeon. At the time of resec-
tion, the location and size of the removed tumor (max-
imum diameter and volume), the relationship to the 
surrounding normal structures, and the frozen surgical 
margins were reviewed and compared to the pre-implant 
treatment plan. 
The number of sources was verified for each patient 
by the AU (authorized user – a qualified radiation on-
cologist) and medical physicist intraoperatively prior 
to insertion. The surgical bed was carefully explored by 
the radiation oncology and surgical oncology teams, and 
the carotid artery or other major vessels, bones, or crani-
al nerves were identified. In order to reduce the risk of 
carotid rupture, osteoradionecrosis, and neuropathies, 
the seeds were carefully positioned into the surgical bed, 
avoiding direct contact with the carotid artery, bone, or 
cranial nerves. The surgeon and radiation oncologist 
(AU) placed the 131Cs seeds in an appropriate orientation 
within the resection bed. The seed strands or mesh were 
secured with surgical clips or sutured by the otorhinolar-
yngology surgeon and the surgical team continued with 
the standard wound closure and/or flap reconstruction 
(Figure 2). 
Flap reconstructions are performed in some HNC re-
section cases regardless of the use of brachytherapy im-
plants; they did not represent additional interventions in 
these patients. Preparation of the flap reconstruction was 
performed before the seeds were implanted into the sur-
gical bed in order to reduce the exposure of the surgical 
team. Flap coverage is the standard of care for head and 
neck reconstruction for salvage surgery of patients with 
recurrent disease, having previously received radiation 
to the surgical site in order to reduce the risk of fistula for-
mation and tissue breakdown post-operatively. Free flaps 
or pedicled myofascial flaps covered the brachytherapy 
implants and brought radiation-naïve tissue to the re-
section bed to promote wound healing. Standard moni-
toring of the reconstructed flap and/or surgical wound 
followed the standard institutional protocol. 
Fig. 2. A) Five strands of either three or four seeds, total-
ing 18 seeds, were implanted for patient 6 following the 
neck dissection for locoregional recurrence; B) A pec flap 
was used in this case for reconstruction to bring radia-
tion-naïve tissue to the resection bed 
A
B
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Although the prescription dose and number of seeds 
were calculated during a preoperative planning session, 
the number of seeds implanted was modified intraoper-
atively to fit the surgical defect and the at-risk area to be 
covered in some cases. Modifications were determined 
jointly by the radiation oncology and surgical oncology 
teams. Additionally, in cases where modifications were 
large, the radiation prescription dose was also lowered 
intraoperatively. 
Implanted number and activity of seeds were docu-
mented on the written directive completed at the end of 
the implant by the AU and the medical physicist. Sources 
not used in the procedure were returned to the radiation 
oncology radioactive storage area, logged in the radiation 
source inventory, and stored for decay per existing insti-
tutional policies. 
Post-implant treatment planning and dose 
calculation 
A non-contrast CT scan with 0.7-2.0 mm thick slices 
and O-MAR artifact reduction protocol was performed 
within 24 hours after the implant for all patients. Patients 
2-5, 10, and 14 were scanned on a Philips Brilliance 64 
scanner with 2.0 mm thick slices. Patients 1, 6-9, 11-13, 
and 15 were scanned on a Philips iCT 256 scanner with 
0.7-2.0 mm thick slices. The implanted seeds were iden-
tified on the post-implant CT, and a post-implant treat-
ment plan was created to confirm the seed location and 
delivered prescription dose. Figure 3 displays the pre-im-
plant and post-implant treatment plan for patient 6. 
Radiation safety 
Cesium-131 was added to our institution’s radiation 
safety license isotope list for quantities necessary for per-
manent implant brachytherapy for patients with recur-
rent resectable HNC. Radiation oncologists were defined 
as AU by the radiation safety office, in accordance with 
state legislature and institutional policy for competency 
in manual brachytherapy. Nursing staff, residents, and 
physicians participating in clinical care for these pa-
tients in the operating room, recovery area, or hospital 
floor received radiation safety refresher training with 
an emphasis on the properties of the 131Cs isotope and 
the implanted sites of the head and neck region. Median 
equivalent dose to surgeons’ hands was measured using 
a ring badge for each of the first six cases individually. 
For subsequent cases, the surgeons were assigned ring 
badges, which were read quarterly. Additional staff were 
assigned body or ring dosimeters as deemed appropriate 
by radiation safety. 
Pre- and post-implant radiation surveys of the patient 
were performed using a Fluke 451B ionization chamber 
survey meter by the medical physicist. The post-implant 
survey was performed after final wound closure. Radia-
tion exposure was measured at 1 m from the surgical site. 
Educational information, including instructions re-
garding radiation safety recommendations were provid-
ed to the clinical staff in the operating room. Instructions 
were subsequently handed off to the recovery room and 
the medical floor nursing teams. Patients returned to the 
recovery room, then regular surgical floor, and remained 
inpatients following the standard surgical recovery proto-
cols. Due to the photon energy of 131Cs and implanted ac-
tivity needed to achieve the desired therapeutic doses, no 
special room or patient precautions were necessary as all 
patients met the United States Nuclear Regulatory Com-
mission (NRC) criteria for release of patients administered 
radioactive material. No shielding was added to the im-
Fig. 3. A) The pre-treatment treatment plan for patient 6. Seed activity of 2.1 U was selected to deliver 60 Gy to 0.5 cm from the 
center of the implant plane; B) The post-implant treatment plan in created by identifying the seeds on the post-implant CT scan. 
In this case, the number of implant seeds and the prescription dose did not change based on intraoperative findings 
A B
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plant site in any of these 15 patients. All patients were edu-
cated prior to implantation on the risk and safety concerns 
regarding radiation exposure. Patients were provided 
written educational information as part of their discharge 
instructions regarding radiation safety recommendations. 
Statistical methods 
The mean and standard deviation were calculated 
for the number of seeds, individual seed strength, and 
final prescription dose for 15 patients. A range of mini-
mum-maximum values was also reported. Generally, for 
radiation safety and personnel dosimetry, mean, standard 
deviation, and range are reported for the patient survey for 
15 implants, and the mean and range of the surgeons’ ring 
badge reading are reported for the first six cases. 
Results 
The average seed strength used for implants was 2.2 
±0.2 U (range, 1.7-2.5 U; 3.5 ±0.3 mCi; range, 2.7-3.9 mCi). 
In five of 15 cases, the number of seeds implanted was 
modified intraoperatively to fit the surgical defect and 
the at-risk area to be covered. In three cases, the radia-
tion prescription was lowered intraoperatively. In two of 
those three cases, the change in number seeds implant-
ed necessitated a prescription change. In the other case 
(patient 14), it was initially planned that 17 seeds would 
be implanted in a single site to deliver 60 Gy. However, 
intraoperative findings led the surgical and radiation on-
cology teams to alter the prescription such that 40 Gy was 
delivered to two separate sites, with 6 seeds in one loca-
tion and 11 in the other. The average final prescription 
dose for 15 patients was 56.1 ±6.6 Gy (range, 40-60 Gy) to 
5 mm from the center of the implanted plane, and an av-
erage of 14 ±6 (range, 4-24) seeds were implanted. Table 1 
presents the seed strength, and the pre- and post-implant 
dose prescriptions as well as number of seeds used. In-
traoperative changes in early cases were attributed to 
the learning curve of the clinicians; improved communi-
cation between the surgeon and the radiation oncology 
teams about the estimated size and geometry of the resec-
tion cavity decreased the number of deviations between 
pre- and post-planned prescriptions and the number of 
seeds implanted. 
Radiation safety 
For the pre-implant survey, the exposure rate at 1 m 
was < 0.1 mR/hr for all patients, which is the expected 
background level of radiation. Following implantation of 
the radioactive sources and conclusion of the surgery, the 
exposure rate was measured again at 1 m from the sur-
gical site, yielding an average of 1.5 ±1.0 mR/hr (0.1-4.0 
Table 1. Seed activity, dose prescription, and number of seeds from the pre- and post-plans for all 15 patients, 
listed in chronological order. Intraoperative changes in the dose prescriptions and number of seeds are indicated 
Patient Seed strength 
(U) 
Pre-implant plan Post-implant plan Intraoperative change 
Dose
prescription 
(Gy) 
Number  
of seeds 
Dose prescrip-
tion (Gy) 
Number  
of seeds 
Dose prescrip-
tion (Gy) 
Number  
of seeds 
1 1.7 60 30 60 24 –6 
2 1.7 66 48 54 20 –12 –28 
3 2.3 60 9 42 4 –18 –5 
4 2.3 60 15 60 15 
5 2.5 60 9 60 9 
6 2.1 60 18 60 18 
7 2.2 60 22 60 22 
8 2.4 60 6 60 6 
9 2.0 56 14 56 14 
10 2.4 60 8 60 10 +2 
11 2.2 50 7 50 7 
12 2.4 60 12 60 12 
13 2.0 60 20 60 20 
14 2.2 60 17 40 17 –20 
15 2.2 60 13 60 17 +4 
Mean 2.2 59.5 16.5 56.1 14.3 
Median 2.2 60.0 14.0 60.0 15.0 
SD 0.2 3.1 10.5 6.6 5.9 
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mR/hr). Median equivalent dose to surgeons’ hands was 
0.60 mSv (range, 0.33-1.48 mSv) for the first six cases. 
Subsequent quarterly thermoluminescent dosimetry 
(TLD) ring and optically stimulated luminescence (OSL) 
body badge measurements were well below acceptable 
ALARA (as low as reasonably achievable) dose limits. 
Discussion 
Surgical resection, when feasible, remains the main-
stay treatment for recurrent HNC, and intraoperative 
interstitial brachytherapy delivered as an adjuvant treat-
ment for this group of patients may improve the treat-
ment outcome and may be associated with fewer compli-
cations, when compared with EBRT re-irradiation [30,31]. 
The use of interstitial brachytherapy remains limited 
in recurrent HNC despite numerous successful published 
reports. This is perhaps due to the lack of familiarity and 
experience with implantation techniques and/or con-
cerns about radiation exposure to personnel. Brachyther-
apy can be delivered via permanent implants or via the 
insertion of high-activity radioisotopes through remov-
able catheters (using high-dose-rate brachytherapy or 
pulsed-dose-rate brachytherapy). Permanent implants 
may be more appropriate and advantageous for recurrent 
HNC patients, as their recurrences often occur in irreg-
ular surfaces that may not be suitable for or may pose 
challenges for catheter-based brachytherapy [31,32]. 
Moreover, recent success with safer ultra-low dose-
rate isotopes has re-stimulated interest in permanent in-
terstitial brachytherapy and prompted our use in recur-
rent head and neck malignancies [33,34,35,36]. 
Cesium-131 is a favorable isotope for use across 
a wide range of tumors and its dose distribution prop-
erties facilitate easy calculation and delivery in the clinic 
[23,24]. Cesium-131 decays via electron-capture and gen-
erates photons with prominent peaks in the 29 to 34 keV 
range. The average photon energy is greater than other 
commonly used permanent seed implant isotopes, name-
ly Palladium-103 (103Pd) and Iodine-125 (125I), which has 
been shown to improve dose homogeneity in some im-
plants [37]. Moreover, 131Cs has a half-life of 9.7 days, 
which is shorter than 103Pd and 125I, delivering the pre-
scribed dose in less time and decreasing the overall ex-
posure to the patient and family. Additionally, a shorter 
half-life improves the quality of the implant by delivering 
dose faster and limiting the time period where seed mi-
gration caused by wound healing could interfere with the 
planed dose distribution [23,24,37]. 
A major benefit of brachytherapy over external beam 
radiation therapy in previously irradiated areas is the ex-
tremely localized deposition of dose. With 131Cs, the dose 
is prescribed to 0.5 cm from the implant plane, and the 
dose falls off to less than 10% of prescription, approxi-
mately 2-3 cm in all directions from the implant plane. 
This dose fall-off and the associated preservation of 
healthy tissues is unachievable even with the most tech-
nologically advanced external beam radiation delivery 
techniques [38]. 
While pre-planning, it is necessary to estimate the 
seed strength and the number of seeds to be implanted; 
the extent of the surgical resection can result in drastic 
anatomical changes from the pre-implant imaging. Thus, 
the number of seeds implanted based on the size and lo-
cation of the surgical cavity was adjusted intraoperative-
ly in five of these first fifteen cases, and the prescription 
dose was decreased in three of the five adjusted cases. 
This reflects the learning curve in anticipating the geom-
etry of the resection cavity and emphasizes the need for 
communication with the surgical team for the purpose of 
pre-planning and seed ordering. 
The risk of radiation exposure to the health care per-
sonnel and patient family members is negligible, and the 
use of 131Cs brachytherapy does not require additional 
shielding or patient precautions based on the prescrip-
tion doses, the total implanted activity, and the location 
of sources used in these patients. Appropriate educational 
information is provided to the health care professionals 
taking care of these patients intra- and post-operatively. 
Discharge instructions regarding radiation safety recom-
mendations are given to the patients and their family. Our 
radiation safety data is promising and coincides with the 
previously published experience. Parashar et al. treated 
28 patients with recurrent HNC and brain tumors, using 
131Cs sources with a median activity of 2.4 U for a total 
prescribed dose of 60-80 Gy. In this cohort, the median ra-
diation exposure rate at the patient skin was 0.43 mSv/hr 
and at 1 meter the exposure was 0.002 mSv/hr. The mini-
mum measurable radiation dose for OSL body badges and 
TLD ring badges was 1 mrem and 30 mrem, respectively. 
Overall, the exposure to radiation oncologist, surgeons, 
and nursing staff was determined to be minimal [24]. 
Implementation of this procedure requires minimal 
equipment and staff resources if an existing brachyther-
apy program is in place. Most low-dose-rate brachyther-
apy software programs are capable of calculating a basic 
treatment plan or secondary dose verification for this 
procedure. Additionally, a nomogram may be an accept-
able substitute for a secondary dose calculation in lieu of 
a formal dose calculation [28]. Point dose dosimetry was 
applied uniformly to all pre- and post-planning due to the 
nature of source placement and the inability to accurate-
ly decipher source orientation on post-implant imaging. 
While permanent implant brachytherapy is common in 
radiation oncology, this may be a new procedure for oth-
er clinical staff involved in an HNC patient’s care. Thus, 
an appropriate introduction into radiation safety and per-
manent seed implants across the care team is essential. 
The radiation dose prescribed by our group concurs 
with that used by other radiation oncology centers in 
the setting of resectable recurrent HNC. A group at MD 
Anderson published their work using 192Ir interstitial 
brachytherapy with median dose of 60 Gy over a total 
duration of 4 days, with salvage surgery for 22 patients 
with recurrent head and neck cancers [33]. All patients 
underwent neck dissection and intraoperative placement 
of high-dose-rate brachytherapy afterloading catheters 
as a part of the salvage treatment. Of the 22 patients, 
19 had extensive extracapsular spread at the time of sur-
gery. Post-operative complications were few, and there 
were no perioperative deaths. Recurrences in the re-irra-
diated necks occurred in 27% of patients. The 2-year re-
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gional control reported by this study was 57%, with a me-
dian time for recurrent disease of 19 months [33]. Grimard 
et al. found similar results by using brachytherapy for 
recurrent head and neck malignancies; irradiation with 
brachytherapy was used as a single-modality treatment 
in almost one half of the patients, with a dose of 60 Gy 
received by 18 of 22 patients (with all patients receiving 
> 55 Gy). Twenty of the remaining patients had surgical 
resection in addition to brachytherapy; the 1 year and 
2 years locoregional control was 50% and 37%, respec-
tively, with acceptable rates of toxicity [34]. Puthawala 
et al. used 192Ir interstitial afterloading brachytherapy de-
livering a median minimum dose of 53 Gy without sur-
gery (40% received concurrent chemotherapy or a radio-
sensitizing agent) in the setting of recurrent neck disease, 
demonstrating a six month local tumor control of 77%; 
however, moderate to severe complications occurred in 
27% of the patients [35]. Similarly, Glatzel et al. reported 
a complete remission rate of only 28% in 51 patients with 
recurrent HNC treated with high-dose-rate brachythera-
py alone without surgical resection, with a median over-
all survival of only 6 months [36]. 
A new technique, intensity modulated brachythera-
py (IMBT) has been used with promising results for the 
treatment of sinonasal carcinomas and tumors invading 
the skull base and recurrent HNC. The image-guided 
adapted planning ensures the correct radiation sources 
position and respects the dosimetric constrains to the sur-
roundings normal structures, possibly further reducing 
the risk of severe complications [10,13,39]. Teudt et al. 
used HDR-IMBT for nine patients with recurrent HNC 
into the cervical lymph nodes [10]. 
The 131Cs seed implant is permanent and unlike high-
dose-rate brachytherapy, does not require the catheters to 
be placed into the surgical bed and maintained in place for 
several days post-operatively until treatment is complete. 
This permanent implant reduces the risk of infection by 
eliminating the need for in-place catheters and additional 
surgical intervention to remove them. Surgical resection 
and the 131Cs implant occur during the same surgical pro-
cedure, and no further surgical intervention is required. 
The surgical bed is defined by the surgical and radiation 
oncology teams intraoperatively, and the seeds strands 
are secured into the surgical bed, at that time. The tech-
nique is easy to implement and requires minimal equip-
ment and staff resources; the risk of radiation exposure 
to the health care personnel and patient family members 
is negligible. From our data and that in previously pub-
lished literature, the use of 131Cs brachytherapy does not 
require additional shielding or patient precautions; how-
ever, this may depend on the position of sources and the 
amount of surrounding tissue [23,24]. A disadvantage 
of permanent implant brachytherapy compared to other 
forms of brachytherapy or EBRT is the inability to modu-
late or control the dose distribution. 
Re-irradiation using external beam radiation may be 
used alone or in combination with surgery or systemic 
therapies, but is associated with significant risk for fistu-
la formation, severe dysphagia, and carotid ruptures, as 
previously discussed [40,41,42]. 
Prospective clinical trials eliminating the patient’s 
tumor and treatment characteristics’ heterogeneity are 
necessary, but unlikely to be done given the rare use 
of these options. The final therapeutic choice should 
depend on a careful review of each individual case in 
a multidisciplinary treatment approach setting, paying 
attention to the general performance status of the pa-
tient and his/her emotional condition, tumor location 
and its relationship with the surrounding critical struc-
tures, previous radiotherapy dose delivered to this area, 
the experience of the treating team, and the available 
treatment facilities. 
Conclusions 
Cesium-131 interstitial brachytherapy is a feasible 
treatment option for previously irradiated patients with 
recurrent, resectable HNC. It should be considered as 
a viable alternative to external beam radiation. Permanent 
seed implants using 131Cs do not pose radiation safety 
concerns to the surgical and nursing staffs, or to patients 
and their family members. Although our current work fo-
cuses on the process of safely treating locoregional recur-
rent, resectable HNC patients with 131Cs brachytherapy, 
future work will emphasize the utilization of this form 
of therapy as a viable treatment option overcoming the 
negative side effects of re-irradiation using external beam 
with or without the combination of surgery and systemic 
therapies for the same patient population. 
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